The announcement, filed with the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, confirms that Zydus MedTech (France) SAS was officially incorporated on April 10, 2025. This new entity will be the vehicle through which Zydus intends to acquire the equity shares of Amplitude Surgical SA.
As previously disclosed on March 11, 2025, Zydus Lifesciences entered into agreements to acquire 85.6% of Amplitude Surgical’s equity shares for €6.25 per share, totaling €256.8 million. Following the completion of this block acquisition, Zydus plans to launch a mandatory simplified cash tender offer for the remaining shares at the same price. The company intends to proceed with a compulsory acquisition of the remaining shares (squeeze-out) and subsequently delist Amplitude Surgical from the exchange if the tender offer conditions are met.
Zydus MedTech (France) SAS has an authorised share capital of €1,000 and a paid-up share capital of €100. The subsidiary is currently an investment company with the immediate objective of acquiring the equity shares of Amplitude Surgical. Zydus MedTech Private Limited, a wholly owned subsidiary of Zydus Lifesciences, has subscribed to 1,000 equity shares of Zydus MedTech (France) SAS for a total consideration of €1,000, including a share capital of €100 and an issuance premium of €900.
This strategic move underscores Zydus Lifesciences’ commitment to expanding its global footprint and strengthens its presence in the orthopedic market. Further updates on the acquisition process will be provided as they become available.
